European Journal of Clinical and Experimental Medicine T.15, z. 2 (2017)

URI dla tej Kolekcji

http://repozytorium.ur.edu.pl/handle/item/3184

Przeglądaj

Przeglądanie European Journal of Clinical and Experimental Medicine T.15, z. 2 (2017) według Autor "Tutka, Piotr"

Aktualnie wyświetlane 1 - 2 z 2
  • Obrazek miniatury
    Pozycja
    19F MRI As a tool for imaging drug delivery to tissue and individual cells
    (Wydawnictwo Uniwersytetu Rzeszowskiego, 2017) Bober, Zuzanna; Aebisher, David; Ożóg, Łukasz; Tabarkiewicz, Jacek; Tutka, Piotr; Bartusik-Aebisher, Dorota
    Over the past few decades, magnetic resonance imaging (MRI) has proven to be extremely successful in medical applications. More recently, the biomedical applications of MRI have been gaining more use in the field of clinical pharmacy. In 1977, perfluorocarbon compounds (PFC), which form emulsions that can carry drugs, were analyzed by 19F MRI and emulsified PFC compounds have been investigated as potential blood substitutes since the early 1960s and now a wide variety of PFC compounds are currently available as 19F MRI biomarkers. Molecules with 19F substituents are particularly attractive for use in drug tracking by 19F MRI due to 100% 19F abundance, high 19F MRI sensitivity (0.83 relative to 1H MRI) and an impressively large chemical shift range (400 ppm). Another benefit in the use of 19F MRI is a zero background signal in biological samples due to lack of endogenous fluorine. Therefore, drugs containing fluorine atom have potential for 19F MRI imaging drug delivery to tissue. This article will review recent developments in the use of 19F MRI in imaging drug delivery to tissue and individual cells.
  • Obrazek miniatury
    Pozycja
    Investigation of pharmaceuticals by nuclear magnetic resonance imaging and spectroscopy
    (Wydawnictwo Uniwersytetu Rzeszowskiego, 2017) Bober, Zuzanna; Aebisher, David; Tabarkiewicz, Jacek; Guz, Wiesław; Tutka, Piotr; Bartusik-Aebisher, Dorota
    Currently, new and easier ways of analyzing pharmaceutical drug forms and drug delivery mechanisms are being sought. Magnetic resonance imaging (MRI) is a non-invasive imaging technique that images drug forms such as tablets, liquids and topicals and drug form behavior in living organisms on both the tissue and cellular scale. The advantages of MRI include noninvasiveness, variable sample capacity and ease of transfer of phantom results to in vitro and in vivo studies. This review concerns the usefulness of clinical MRI that cannot be understated as this technique provides non-invasive and non-destructive insight into the properties of drug delivery systems. The research discussed here concerns the use of magnetic resonance, spectroscopy and chromatography to investigate selected pharmaceuticals and covers work of selecting drugs and antibodies for modification by synthesis for evaluation by MRI. Modifications have been aimed at improving therapeutic efficacy, delivery, and MRI. Modification conditions such as (pH, concentration, temperature, and the influence of other components present in the solutions) will be discussed to understand drug delivery system improvements and the reliability and repeatability of the results obtained. We hope to explore and expand the scope of pharmaceutical imaging with MRI for application in clinical medicine.